drugset / Trial / NCT05642455
SPEARHEAD-3 Pediatric Study
NaSingle-groupOpen-labelTreatment
Summary
This is a pediatric basket study to investigate the safety and efficacy of afamitresgene autoleucel in HLA-A\*02 eligible and MAGE-A4 positive subjects aged 2-17 years of age with advanced cancers.
Timeline
- Start
- 2023-09-01
- Primary completion
- 2026-10-01
- Completion
- 2038-07-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | afamitresgene autoleucel | Cell therapy | 2.5e+07 cells/kg | Intravenous |
| Subject | afamitresgene autoleucel | Cell therapy | 2e+08 cells/kg | Intravenous |
| Subject | afamitresgene autoleucel | Cell therapy | 1e+09 cells | Intravenous |
| Subject | afamitresgene autoleucel | Cell therapy | 1e+10 cells | Intravenous |